As with everything during the global COVID-19 pandemic, pulmonary fibrosis clinical trials and PACT activities were majorly impacted. Thank you for your patience with any delays you may encounter when enquiring about a trial.
Thank you to all involved in the (ongoing) clinical response to COVID-19. To stay up to date with PACT,Become a member
PACT partnership with HealthMatch to help patients access clinical trials
Finding and accessing clinical trials can be difficult for Pulmonary Fibrosis patients. PACT has partnered with HealthMatch to make this process easier and more efficient. Use the link below to find out more about matching for current and future Pulmonary Fibrosis clinical trials and create a profile.Visit HealthMatch
Over the past decade high quality trials have transformed treatment approaches for patients with PF both by ensuring patients are not exposed to potentially harmful treatments and by supporting access to treatments with proven efficacy. Find out more in the Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia, here.
Enrollment in clinical trails is now considered standard of care for patients with pulmonary fibrosis, much as it is for patients with cancer. Clinicians – be they PF ‘experts’ or not – have a vital role to play in encouraging enrollment in high quality clinical trials, especially since PF is an uncommon disease impeding recruitment to very large trials. Below are links to Pulmonary Fibrosis trials currently recruiting in Australasia.
|STARSCAPE WA42293||A phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with Idiopathic Pulmonary Fibrosis.||Recruiting|
|GALACTIC-1||A randomised, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in participants with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of GB0139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler (DPI) over 52 weeks.||Recruiting|
|TELO-SCOPE||Attenuating Telomere Attrition with Danazol. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis.||Recruiting|
|PFOX||PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial||Recruiting||Trial SummaryClinicaltrials.gov ID: NCT03737409|
|HIIT||High intensity interval training in fibrotic interstitial lung disease||Recruiting||Trial Summary
Clinicaltrials.gov ID: NCT03800914
|GRIPF||Genetic research in Idiopathic Pulmonary Fibrosis (GRIPF)||Recruiting||Trial Summary
Trials Closed to Recruitment
|BI 1305-0013||A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally.||Closed to Recruitment||Clinicaltrials.gov ID: NCT04419506|
|ATLAS AP01-002||A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis||Closed to Recruitment||Clinicaltrials.gov ID: ACTRN12618001838202|
|Trail1||A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease (RAILD)||Closed to recruitment The TRAIL1 study continued enrolment through the planned timeline, but was somewhat impacted by COVID and did not meet enrolment goals.||Clinicaltrials.gov ID: NCT02808871|
|AGN120-1||An Open Label Study of the Efficacy, Safety and Tolerablity of Np-120 on Idiopathic Pulmonary Fibrosis and its Associated Cough||Closed to Recruitment||Clinicaltrials.gov ID: NCT04318704|
|Zephyrus FGCL-3019-091||FGCL-3019-091 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF).||Closed to recruitment||Clinicaltrials.gov ID: NCT03955146|
|BMS IM027-040||A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis.||Closed to recruitment|
|HHF-ILD||Handheld fan for breathlessness in interstitial lung disease||Recruiting||Clinicaltrials.gov ID: ACTRN12618001838202|
|COLDICE||Cryobiopsy versus Open Lung biopsy in the Diagnosis of Interstitial lung disease allianCE||Study completed||Clinicaltrials.gov ID: ACTRN12615000718549|
|SCENIC||Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial||Discontinued
The SCENIC study was terminated due to the impact of COVID-19. The study was being conducted across 11 countries and while the impact was minimal in Australasia this was not the case in the other regions.
|Clinicaltrials.gov ID: NCT03864328|
|Isabela 1&2||A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With ldiopathic Pulmonary Fibrosis||Discontinued
The decision to discontinue the ISABELA Phase 3 clinical studies was based on the recommendations of the Independent Data Monitoring Committee (IDMC) which, following a regular review of unblinded data, concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies.
|Clinicaltrials.gov ID: NCT0371l-162
Clinicaltrials.gov ID: NCT03733444
|Blade Therapeutics||A Phase 1a/1b, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BLD-2660 in Healthy Volunteers and Subjects with Lung Fibrosis or Liver Fibrosis||Discontinued||Clinicaltrials.gov ID: NCT03559166|
|SPIRIT||A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis (IPF)||Discontinued||Clinicaltrials.gov ID: NCT03573505|